NASDAQ$DSGN
Design Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Provided pipeline updates and reported first quarter 2023 financial results.
Design Therapeutics reported its first quarter 2023 financial results, highlighting progress in its GeneTAC™ small molecule pipeline. Initial data from the Phase 1 multiple-ascending dose trial of DT-216 for Friedreich Ataxia is expected in the third quarter of 2023. The company's cash and securities are expected to support operating runway through 2025.
- Initial data from Phase 1 multiple-ascending dose trial of DT-216 for Friedreich Ataxia expected in the third quarter of 2023.
- Progress across GeneTAC™ small molecule pipeline with IND submissions for FECD and DM1 programs on-track for the second half of 2023 and 2024, respectively.
- Cash and securities of $315.4 million expected to support operating runway through 2025.
- Preparing to submit a second Investigational New Drug application (IND) in the second half of this year to support development of our novel DT-168 eye drop for patients with Fuchs endothelial corneal dystrophy (FECD).
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Design Therapeutics anticipates several milestones, including initial data from the Phase 1 MAD trial of DT-216, IND submission for DT-168 for FECD, and IND submission for the DM1 program.
Tailwinds
- Initial data from Phase 1 MAD trial of DT-216 for FA expected in Q3 2023.
- IND submission on-track for DT-168 for FECD in the second half of 2023.
- IND submission on-track for DM1 Program in the second half of 2024.
- Sufficient cash to fund operating plan through 2025.
- Advancing preclinical characterization of lead GeneTAC™ molecules for DM1.
Headwinds
- An unanticipated vendor issue related to the study drug vial stopper caused a short delay in product supply for DT-216.
- Early-stage programs are subject to projections and may not yield expected results.
- Preclinical and early-stage clinical data may not translate to later stages.
- Clinical trial and patient enrollment are affected by many factors, which may cause delays.
- Reliance on third parties to conduct clinical trials and preclinical studies poses risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro